Ionis says Roche Phase 3 IMAgINATION interim data show sefaxersen cuts proteinuria in IgA nephropathy
IONS•IONS•IONS•IONS•The blinded study continues, with a longer-term kidney function readout expected at week 105.
Ionis reported positive prespecified interim Phase 3 IMAgINATION results for Roche-partnered sefaxersen in adults with primary IgA nephropathy.
The interim findings have not yet been presented; Roche plans to present them at an upcoming medical meeting.
Sefaxersen reduced signs of kidney damage versus placebo, supporting its potential to slow disease progression.
Safety was consistent with earlier data, with no new safety signals.
